Alzheimer's disease (AD) is the most common cause of cognitive impairment in older patients and is expected to increase greatly in prevalence. Neuropathologically, AD is characterized by beta-amyloid containing plaques, tau-containing neurofibrillary tangles, and neuronal loss. A well described yet underappreciated eariy feature of AD pathogenesis is the degeneration ofthe locus coeruleus (LC), which is the sole source of forebrain norepinephrine (NE). Previous studies have shown that LC lesions exacerbate AD-like neuropathology and cognitive deficits in mouse models of AD, while increasing NE is neuroprotective. However, the mechanism underiying the protective effect of LC neurons in AD is not understood. We have recently discovered that NE and other endogenous catecholamines function as direct agonists forthe TrkB neurotrophin receptor. TrkB signaling is neuroprotective, retards A(3 toxicity, and is critical for neuronal plasticity and learning and memory. The goal of this proposal is to test whether this novel NE-TrkB interaction contributes to the role ofthe LC in AD pathogenesis.
In Aim 1, we will test the ability of NE and novel synthetic catecholamine-derived TrkB agonists to decrease AB production and toxicity in primary neuronal cultures.
In Aim 2, we will test the ability of the most promising TrkB agonists identified in Aim 1 to ameliorate AD-like neuropathology and cognitive deficits in a transgenic mouse model of AD.
In Aim 3, we will test the hypothesis that LC loss in mild cognitive impairment (MCI) and AD impairs TrkB activation and correlates with amyloid pathology and cognitive impairment using human postmortem cases.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG025688-10
Application #
8662669
Study Section
Special Emphasis Panel (ZAG1-ZIJ-4)
Project Start
Project End
Budget Start
2014-05-01
Budget End
2015-04-30
Support Year
10
Fiscal Year
2014
Total Cost
$190,801
Indirect Cost
$67,703
Name
Emory University
Department
Type
DUNS #
066469933
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Barnes, Josephine; Bartlett, Jonathan W; Wolk, David A et al. (2018) Disease Course Varies According to Age and Symptom Length in Alzheimer's Disease. J Alzheimers Dis 64:631-642
Schaffert, Jeff; LoBue, Christian; White, Charles L et al. (2018) Traumatic brain injury history is associated with an earlier age of dementia onset in autopsy-confirmed Alzheimer's disease. Neuropsychology 32:410-416
Kotlar, Alex V; Trevino, Cristina E; Zwick, Michael E et al. (2018) Bystro: rapid online variant annotation and natural-language filtering at whole-genome scale. Genome Biol 19:14
Walker, Lary C (2018) Prion-like mechanisms in Alzheimer disease. Handb Clin Neurol 153:303-319
Burke, Shanna L; Maramaldi, Peter; Cadet, Tamara et al. (2018) Decreasing hazards of Alzheimer's disease with the use of antidepressants: mitigating the risk of depression and apolipoprotein E. Int J Geriatr Psychiatry 33:200-211
Davis, Jeremy J (2018) Performance validity in older adults: Observed versus predicted false positive rates in relation to number of tests administered. J Clin Exp Neuropsychol 40:1013-1021
Jucker, Mathias; Walker, Lary C (2018) Propagation and spread of pathogenic protein assemblies in neurodegenerative diseases. Nat Neurosci 21:1341-1349
Rangaraju, Srikant; Dammer, Eric B; Raza, Syed Ali et al. (2018) Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer's disease. Mol Neurodegener 13:24
Qian, Winnie; Fischer, Corinne E; Schweizer, Tom A et al. (2018) Association Between Psychosis Phenotype and APOE Genotype on the Clinical Profiles of Alzheimer's Disease. Curr Alzheimer Res 15:187-194
Lin, Ming; Gong, Pinghua; Yang, Tao et al. (2018) Big Data Analytical Approaches to the NACC Dataset: Aiding Preclinical Trial Enrichment. Alzheimer Dis Assoc Disord 32:18-27

Showing the most recent 10 out of 444 publications